← Back to Briefing

New pill nearly doubles survival time for pancreatic cancer patients

New pill nearly doubles survival time for pancreatic cancer patients

Researchers say the pill, daraxonrasib, works by blocking a mutated protein that fuels tumor growth in more than 90% of pancreatic cancer cases.

Story image
Continue reading

This preview is provided by The Woodlands News. Full article available at .